Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Shun Tsunoda"'
Autor:
Shuku Sato, Wataru Kamata, Kiyomitsu Fukaguchi, Shun Tsunoda, Tadashi Kamio, Hiroshi Koyama, Hideyasu Sugimoto, Yotaro Tamai
Publikováno v:
Journal of Medical Case Reports, Vol 16, Iss 1, Pp 1-6 (2022)
Abstract Background Invasive pulmonary Aspergillus and invasive bronchial aspergillosis is a life-threatening opportunistic fungal infection that predominantly affects immunocompromised hosts. A case series and review found that the mortality rate of
Externí odkaz:
https://doaj.org/article/388234f2dca84d34ae3e398345beefc2
Autor:
Hiroe Aramaki, Kiyomitsu Fukaguchi, Hiroshi Yamagami, Yuki Maeda, Shun Tsunoda, Kenichiro Akazawa, Hiroshi Koyama
Publikováno v:
Respirology Case Reports, Vol 11, Iss 2, Pp n/a-n/a (2023)
Abstract We describe the case of a 67‐year‐old man with shock and hypoxemia. Chest X‐ray showed bilateral lung mass shadows and left pleural effusion with a mediastinal shift, suggesting malignancy. Physical examination and point‐of‐care ul
Externí odkaz:
https://doaj.org/article/a123bd8ed08f40059ba7e0c426317ef9
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Myeloproliferative neoplasms (MPNs) are caused by genetic abnormalities in the stem cells and manifest with various systemic symptoms. Here, we describe a case of MPN complicated by alopecia areata. A 51-year-old woman visited our hematology departme
Externí odkaz:
https://doaj.org/article/d6e417db22204fbdbe8b3faa3ac8da47
Publikováno v:
Annals of Hematology. 102:1185-1191
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard treatment for symptomatic multiple myeloma (MM) in patients under 65 years of age. However, the performing of ASCT in older patients > 65 years without com
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 63(3)
This paper reports a case of a 56-year-old male with IgG lambda plasmablastic myeloma exhibiting multiple chromosomal abnormalities. The patient initially presented with plasmablastic ascites and underwent early auto stem cell transplantation and ach
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S299
Background and Aim: Arsenic trioxide (ATO), a safe and effective treatment for acute promyelocytic leukemia (APL), has an effective plasma arsenic concentration (PAC) of 37.6–150 ng/mL. According to current recommendations, the ATO dosage should be
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S218
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S232-S233
Background and Aim Tyrosine kinase inhibitors (TKIs) have substantially improved the prognosis of chronic myeloid leukemia (CML). However, TKIs can cause serious vascular adverse events (VAEs) such as ischemic heart disease (IHD), peripheral artery o
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS299-S299, 1p